Why the study?
Low-dose DOACs combined with antiplatelet therapy (dual-pathway inhibition) have been tested to prevent ischaemic events in CVD, but the overall safety and efficacy needed systematic determination.
Does low-dose DOAC added to antiplatelet therapy reduce major adverse cardiovascular events in patients with cardiovascular disease?
Does low-dose DOAC added to antiplatelet therapy reduce major adverse cardiovascular events in patients with cardiovascular disease?
In patients with cardiovascular disease, dual-pathway inhibition with low-dose DOACs and antiplatelet therapy reduces ischemic events at the cost of increased bleeding, though very low-dose regimens (e.g., rivaroxaban 2.5 mg twice daily) may offer a favorable risk-benefit profile.
No takes yet. Share an insight, caveat, or question.
Requires individualized ischemic-bleeding risk assessment before DPI; confirms COMPASS/ATLAS and extends very-low-dose ICH safety.
Galli et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: